Cancer Genetics, Inc. (Nasdaq: CGIX) announced that it received New York State approval for its Focus::CLL™ panel, a unique next ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE